Merrill Lynch maintains UCB at buy

UCB was reiterated by Merrill Lynch analyst Erica Whittaker at a buy rating with a €48 share price objective after abstracts from a phase III trial of Cimzia to treat Crohn's disease appeared positive and Humira abstracts suggest better efficacy with double the recommended dose in a phase III Crohn's study. Merrill Lynch said it expects Cimzia to be the company's next growth driver with $900 million in sales by 2013 after its 2007 launch. Shares of the Brussels, Belgium-based biopharmaceutical company were unchanged at $53.50.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.